The market correctly sees biology's potential but often misunderstands its timeline. Even with AI, biology is fundamentally harder and slower than software. Daniel Fero warns this mismatch in "tempo" expectations leads to over-funding hype cycles while under-funding foundational companies that are simply moving at the pace required for rigorous biological R&D.

Unlike tech investing, where a single power-law outlier can return the entire fund, biotech wins are smaller in magnitude. This dynamic forces biotech VCs to prioritize a higher success rate across their portfolio rather than solely hunting for one massive unicorn.

Lacking capital, Derek Small was forced to personally write grants and lead regulatory affairs. This hands-on, "virtual company" approach, born of necessity, gave him a profound, holistic understanding of the science and operations he wouldn't have gained otherwise.

Life science investing is inherently tougher than tech because its best-case returns are around 10x, whereas tech can achieve 1000x. This means a single 10x biotech winner cannot compensate for 9 failures in a portfolio, forcing a more capital-disciplined approach to investment and risk management.

Fundraising as a first-time biotech CEO is not a single skill. Ron Cooper's experience at Albareo involved executing seven different financial transactions in two years, most of which were new to him. This demonstrates that success requires intense persistence ("wearing out your shoe leather"), a compelling story, and creativity in pursuing non-traditional financing.

While biotech cannot easily replicate tech's rapid iteration cycles due to high costs and long feedback loops, it can adopt the capital efficiency model of tech seed investing. The strategy is to kill flawed projects quickly and cheaply, ensuring that when you lose, you lose small.

Scientific founders must shift from detailing R&D progress to telling a compelling story. Investors are less moved by specific experimental results and more by the vision of a platform technology at the cusp of major trends (like SynBio and AI) that can generate a continuous pipeline of future therapies.

The path for biotech entrepreneurs is a long slog requiring immense conviction. Success ("liftoff") isn't just a clinical trial result, but achieving self-sustaining profitability and growth. This high bar means founders may need to persevere through years of market indifference and financing challenges.

Early-stage biotech investing is less about quantitative analysis, as companies lack cash flow for traditional valuation. The primary skill is identifying founders who lack deep domain expertise, citing Y Combinator founders who didn't understand the CPT billing codes their company was based on.